Sarcopenia and the inflammatory cytokines

Arkadiusz Orzechowski

DOI: https://doi.org/10.1016/b978-0-12-822146-4.00008-9

2021-01-01

Abstract:Sarcopenia is a loss of skeletal muscle mass and strength due to a reduced number of myofibers. The atrophied muscle should not be mistaken for cachexia (muscle wasting) even though sarcopenia could accompany the latter. There are numerous causes of sarcopenia, including neuropathic (absence of nerve supply), such as loss of motor neurons (central and peripheral), and myopathic (muscle diseases). The term neuromuscular disease is addressed to disorders of both motor neurons, peripheral nerves, neuromuscular junctions, and muscle itself. Diminished input of anabolic hormones or sensitivity thereof (sex steroids, insulin), increased catabolism (glucocorticoids), and finally, the harmful effects of an imbalance between activities of anti- and proinflammatory cytokines (herewith inflammatory) contribute to sarcopenia. The clinical importance of sarcopenia in human beings becomes evident in the elderly when physical disability paralleled by greater visceral fat leads both to a higher incidence of metabolic syndrome (MS) and cardiovascular disease (CVD). The muscle–fat crosstalk points to the considerable role played by adipokines and myokines. It is clear now that some of the inflammatory cytokines stem from adipocytes and myofibers (TNF-alpha and IL-6, respectively). The consequences of sarcopenia such as physical frailty, falls, disability, abnormal deglutition together with CVD are liable for higher mortality rates. Thus, deciphering the pathogenesis of sarcopenia is of paramount significance to improve human health and wellbeing.